8MV0 — Bioharvest Sciences Income Statement
0.000.00%
Last trade - 00:00- €95.30m
- €105.36m
- $25.19m
Annual income statement for Bioharvest Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.396 | 2.1 | 5.5 | 12.7 | 25.2 |
| Cost of Revenue | |||||
| Gross Profit | 0.138 | 0.67 | 1.22 | 5.63 | 13.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 6.56 | 10.6 | 16.1 | 22.6 | 32.2 |
| Operating Profit | -6.17 | -8.49 | -10.6 | -9.97 | -6.99 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.58 | -9.83 | -11.2 | -12.6 | -12.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.58 | -9.83 | -11.2 | -12.6 | -12.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.58 | -9.83 | -11.2 | -12.6 | -12.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.58 | -9.83 | -11.2 | -12.6 | -12.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.616 | -0.789 | -0.861 | -0.928 | -0.797 |